# Isolated Adrenocorticotropin Deficiency With Depressive Symptoms

**Authors:** Kentaro Mikami, Yasushi Oiwa, Mitsuhiro Kometani, Takashi Yoneda, Masashi Oe, Yuko Katsuda

PMC · DOI: 10.1210/jcemcr/luaf304 · JCEM Case Reports · 2026-02-24

## TL;DR

An 81-year-old woman with depressive and gastrointestinal symptoms was diagnosed with a rare adrenal disorder that improved with hormone therapy.

## Contribution

Highlights IAD as a rare but reversible cause of unexplained symptoms in older adults.

## Key findings

- The patient showed markedly low cortisol and ACTH levels, confirmed by a stimulation test.
- Hydrocortisone therapy rapidly improved symptoms and consciousness.
- IAD should be considered in older patients with unresponsive psychiatric and gastrointestinal symptoms.

## Abstract

Isolated adrenocorticotropin deficiency (IAD) is a rare cause of adrenal insufficiency, often presenting with nonspecific symptoms that can be misattributed to mental disorders or gastrointestinal diseases, particularly in older adults. IAD is characterized by profoundly reduced adrenocorticotropin (ACTH) secretion with preserved secretion of other anterior pituitary hormones. We describe an 81-year-old woman with persistent nausea, vomiting, anorexia, and depressive symptoms that did not respond to standard antidepressant agents. During 2 months of hospitalization, she progressed to impaired consciousness. Routine laboratory tests and magnetic resonance imaging of the pituitary region revealed no abnormalities. Hormonal evaluation showed markedly low levels of cortisol and ACTH. A corticotropin-releasing hormone stimulation test confirmed IAD. The patient had no history of glucocorticoid use, immune checkpoint inhibitors therapy, or other causes of adrenal insufficiency. Intravenous hydrocortisone replacement therapy at 50 mg daily led to a rapid improvement in consciousness and resolution of psychiatric gastrointestinal symptoms. This case emphasizes the importance of considering IAD in older patients presenting with unexplained neuropsychiatric and gastrointestinal symptoms, particularly when standard therapies are ineffective. Early diagnosis and hormone replacement therapy are critical as delayed recognition may lead to life-threatening deterioration, but the condition remains reversible with appropriate management.

## Linked entities

- **Chemicals:** hydrocortisone (PubChem CID 5754)
- **Diseases:** adrenal insufficiency (MONDO:0000004), ischemic colitis (MONDO:0000701)

## Full-text entities

- **Genes:** POMC (proopiomelanocortin) [NCBI Gene 5443] {aka ACTH, CLIP, LPH, MSH, NPP, OBAIRH}, PRL (prolactin) [NCBI Gene 5617] {aka GHA1, pPRL}, CRH (corticotropin releasing hormone) [NCBI Gene 1392] {aka CRF, CRH1}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}
- **Diseases:** amnesia (MESH:D000647), metabolic abnormalities (MESH:D008659), hypotension (MESH:D007022), neurological dysfunction (MESH:D009461), major depressive disorder (MESH:D003865), IAD (MESH:C565377), vomiting (MESH:D014839), empty sella syndrome (MESH:D004652), coma (MESH:D003128), cognitive impairment (MESH:D003072), neurological deterioration (MESH:D009422), Depression (MESH:D003866), autoimmune disease (MESH:D001327), multiorgan dysfunction (MESH:D009102), nausea (MESH:D009325), nausea and vomiting (MESH:D020250), unresponsiveness (MESH:C567934), loss of appetite (MESH:D001068), tuberculosis (MESH:D014376), fatigue (MESH:D005221), Adrenal insufficiency (MESH:D000309), endocrine disorder (MESH:D004700), cancer (MESH:D009369), gastrointestinal complaints (MESH:D005767), diabetes mellitus (MESH:D003920), hypoglycemia (MESH:D007003), mental disorders (MESH:D001523), hyponatremia (MESH:D007010), anorexia (MESH:D000855), ACTH deficiency (MESH:C562707), adrenal crisis (MESH:D000310), edema (MESH:D004487), uterine leiomyoma (OMIM:150699), cortisol deficiency (MESH:C535280), weight loss (MESH:D015431), abdominal pain (MESH:D015746), pituitary dysfunction (MESH:D010900), pseudodementia (MESH:D005162), hyperlipidemia (MESH:D006949), appendicitis (MESH:D001064), catatonia (MESH:D002389), neuropsychiatric and gastrointestinal symptoms (MESH:D012817), trauma (MESH:D014947), skin hyperpigmentation (MESH:D017495), Adrenocorticotropin Deficiency (MESH:D007153), hypothyroidism (MESH:D007037), adrenal crises (MESH:D013224), Sheehan syndrome (MESH:D007018), hypertension (MESH:D006973), brain lesions (MESH:D001927), altered consciousness (MESH:D003244), hypophysitis (MESH:D000072659)
- **Chemicals:** alcohol (MESH:D000438), duloxetine (MESH:D000068736), mirtazapine (MESH:D000078785), Cortisol (MESH:D006854), sodium (MESH:D012964), Oxygen (MESH:D010100), olanzapine (MESH:D000077152)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12930356/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12930356/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12930356/full.md

---
Source: https://tomesphere.com/paper/PMC12930356